Global biomanufacturing trends, capacity, and technology drivers
By: P. Seymour
DCAT Week; 2016 Mar 14-17; New York, NY.
Biologic-based drugs are an increasingly important part of the product growth strategies for pharmaceutical and biopharmaceutical companies. As the number of commercial products and pipeline candidates grows, a crucial issue facing the industry is the current and future state of biomanufacturing capacity, the availability of that capacity, and the technologies impacting upstream and downstream bioprocessing. Pharmaceutical and biopharmaceutical companies and contract manufacturing organizations (CMOs) are aligning their strategies to not only address capacity but to address greater complexity in supplier risk, the competitive forces of innovator biologics and biosimilars, and the adoption of advanced biomanufacturing technologies.